Pfizer Hellas: «Η Αθήνα υπήρξε φαρμακευτικός παράδεισος»

«Η Αθήνα υπήρξε φαρμακευτικός παράδεισος, γιατί η κατανάλωση φαρμάκων ήταν από δύο έως τρεις φορές υψηλότερη από ό,τι σε άλλες ευρωπαϊκές χώρες και το κράτος αναλάμβανε την πληρωμή τους, όμως η κατάσταση άλλαξε μετά τη λήψη μέτρων λιτότητας, γιατί η κυβέρνηση της χώρας περιόρισε κατά 35% τον προϋπολογισμό για την αγορά φαρμάκων» δήλωσε ο γενικός διευθυντής της φαρμακευτικής εταιρείας Pfizer Ελλάς Α.Ε., Πιέρ Γκοντρό, στη γαλλόφωνη εφημερίδα του Καναδά «Λα Πρες» (La Presse).

What physicians want

Every two years Publicis Touchpoint and Sermo release poll results about what physicians want titled, not surprisingly, “What Physicians Want!” You can get the full white paper from the Touchpoint website.

As both a research creator and consumer I find it important to highlight the selection bias that is rampant in this document. Sermo, as is well known, is North America’s largest physician-only social network with over 120,000 members. It stands to reason that the physicians that use Sermo will be at the top-end of digital adoption, so expect any questions regarding how they prefer to receive information to be biased in that direction. Further, the answering physicians were overwhelmingly primary care physicians (PCPs) with only 38% specialists in various fields. The top 10 findings, verbatim from the study:

GSK and Yale to work on new class of medicines

UK drug giant GlaxoSmithKline has hooked up with Yale University under a collaboration that will focus on designing a potential new class of medicines. Under the discovery pact, GSK scientists are putting their heads together with Yale researchers to build on the latter's pioneering work with so-called proteolysis targeting chimeric molecules (PROTACs).